Interviews

Dr. Peter Voorhees discusses the evolving treatment landscape for smoldering multiple myeloma, highlighting new therapies and clinical trial opportunities.

Dr. Peter Voorhees discusses risk stratification in smoldering multiple myeloma, highlighting the IMWG criteria and the benefits of daratumumab treatment.

Peter Voorhees, MD, discusses groundbreaking AQUILA study results, highlighting daratumumab's significant impact on high-risk smoldering multiple myeloma treatment.

Che-Kai Tsao, MD, MS, discusses new approaches that could change the standard of care for metastatic hormone-sensitive prostate cancer.

Peter Voorhees, MD, discusses the AQUILA study's impact on treating patients with high-risk smoldering multiple myeloma, paving the way for new therapies.

Emerging MRD tests show promise in enhancing breast cancer treatment by improving risk stratification and clinical outcomes for patients.

Expert explores innovative strategies for managing early stage breast cancer, focusing on minimal residual disease and potential treatment adjustments.

Early-stage breast cancer patients face challenges with ctDNA detection, highlighting the need for clinical trials to improve outcomes and reduce recurrence risks.

Explore the advancements in minimal residual disease (MRD) assays, comparing tumor-informed and tumor-agnostic methods for enhanced cancer detection and treatment strategies.

Emerging research highlights the challenges and potential of ctDNA in managing minimal residual disease in breast cancer, paving the way for innovative treatment strategies.

Circulating tumor DNA (ctDNA) revolutionizes minimal residual disease detection, offering a less invasive, real-time method to monitor cancer and guide treatment.

FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention.

Andrew M. Brunner, MD, discusses challenges and progress in identifying treatment for patients with transfusion-dependent myelodysplastic syndromes.

Dr Benjamin George champions patient-centered oncology in rural Nebraska, enhancing local cancer care access and fostering community support for patients.

A recent study reveals cognitive behavioral therapy significantly enhances lung cancer patients' ability to manage dyspnea and anxiety, improving overall quality of life.

Dr. Christian S. Hinrichs discusses the future of specialized cell therapies, predicting broader access for community clinics similar to CAR T cell treatments.

Dr. Hinrichs emphasizes the critical need for early referrals and screenings for patients considering advanced cell therapies, enhancing treatment outcomes.

Dr. Christian S. Hinrichs discusses promising results from a phase 2 study on engineered TCR-T cell therapy for HPV-associated cancers.

Hinrichs discusses groundbreaking findings on TIL therapy for HPV-related cancers, highlighting long-term disease-free outcomes in patients.

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, transforming treatment options for patients.

Highlands Oncology's innovative remote monitoring model enhances cancer care, reducing ED visits and improving treatment adherence through effective symptom management.

Che-Kai Tsao, MD, MS, discusses the current state of treatment for metastatic hormone-sensitive prostate cancer.

A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its potential as a frontline treatment.

Experts discuss the evolving strategies in managing immune-related adverse events in cancer treatment, emphasizing precision immunomedicine and patient history.

Frederick L. Locke, MD, discusses the 2025 removal of the REMS program for CAR T-cell therapy and the resulting improvements to patient access.

Discover evolving strategies for managing immune-related adverse events in cancer immunotherapy, enhancing decision-making for oncologists and practitioners.

Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues and achalasia in patients.

Dr. Michael Soulen discusses safety concerns and adverse events in neuroendocrine tumor treatments, highlighting cytopenia and radiation risks while ensuring patient safety.

Chandler H. Park, MD, discusses real-world data for maintenance avelumab in bladder cancer and factors that sway his treatment selection.

Jason S. Starr, DO, discusses the significance of the extrapancreatic neuroendocrine tumor cohort of the phase 3 CABINET trial of cabozantinib.